This serves as an important control on the progression of renal disease in T2DM, wherein chronic hyperglycemia results in increased SGLT-2 expression in the proximal convoluted tubule with enhanced glucose and sodium reabsorption and the blunting of tubuloglomerular feedback. SGLT-2 inhibitors also reduce GLUT2 protein expression in the kidneys, resulting in reduced glucose transport to the serum at the basolateral membrane [37]. The gene discussed is SLC5A2; the disease is kidney disorder.